Glimepiride is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults in the treatment of noninsulin-dependent (type 2) diabetes mellitus. Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive channel, which reduces potassium conductance and causes depolarization of the membrane. Membrane depolarization stimulates calcium ion influx and the increase in intracellular calcium ion concentrations induces the secretion of insulin.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Glimepiride, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.